PanDrugs2: prioritizing cancer therapies using integrated individual multi-omics data.

ABSTRACT: Genomics studies routinely confront researchers with long lists of tumor alterations detected in patients. Such lists are difficult to interpret since only a minority of the alterations are relevant biomarkers for diagnosis and for designing therapeutic strategies. PanDrugs is a methodology that facilitates the interpretation of tumor molecular alterations and guides the selection of personalized treatments. To do so, PanDrugs scores gene actionability and drug feasibility to provide a prioritized evidence-based list of drugs. Here, we introduce PanDrugs2, a major upgrade of PanDrugs that, in addition to somatic variant analysis, supports a new integrated multi-omics analysis which simultaneously combines somatic and germline variants, copy number variation and gene expression data. Moreov

SUBMITTER: Jimenez-Santos MJ 

PROVIDER: S-EPMC10320188 | biostudies-literature | 2023 Jul

REPOSITORIES: biostudies-literature